These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22052917)

  • 1. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study.
    Penn MS; Ellis S; Gandhi S; Greenbaum A; Hodes Z; Mendelsohn FO; Strasser D; Ting AE; Sherman W
    Circ Res; 2012 Jan; 110(2):304-11. PubMed ID: 22052917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy.
    Dill T; Schächinger V; Rolf A; Möllmann S; Thiele H; Tillmanns H; Assmus B; Dimmeler S; Zeiher AM; Hamm C
    Am Heart J; 2009 Mar; 157(3):541-7. PubMed ID: 19249426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction.
    Medicetty S; Wiktor D; Lehman N; Raber A; Popovic ZB; Deans R; Ting AE; Penn MS
    Cell Transplant; 2012; 21(6):1109-20. PubMed ID: 22004910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery.
    Yang Z; Zhang F; Ma W; Chen B; Zhou F; Xu Z; Zhang Y; Zhang D; Zhu T; Wang L; Wang H; Ding Z; Zhang Y
    Cardiovasc Ther; 2010 Dec; 28(6):380-5. PubMed ID: 20337639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial.
    Heeger CH; Jaquet K; Thiele H; Zulkarnaen Y; Cuneo A; Haller D; Kivelitz D; Schmidt T; Krause K; Metzner A; Schneider C; Kuck KH; Bergmann MW
    EuroIntervention; 2012 Oct; 8(6):732-42. PubMed ID: 23086792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
    Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
    Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial.
    Tendera M; Wojakowski W; Ruzyłło W; Chojnowska L; Kepka C; Tracz W; Musiałek P; Piwowarska W; Nessler J; Buszman P; Grajek S; Breborowicz P; Majka M; Ratajczak MZ;
    Eur Heart J; 2009 Jun; 30(11):1313-21. PubMed ID: 19208649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rapid resolution of ST segment elevation predicts recovery of left myocardial contraction in patients with acute myocardial infarction treated with percutaneous coronary angioplasty].
    Tomaszuk-Kazberuk A; Korecki J; Kochman W; Dobrzycki S; Musiał WJ
    Przegl Lek; 2002; 59(8):638-41. PubMed ID: 12638338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.
    Meyer GP; Wollert KC; Lotz J; Steffens J; Lippolt P; Fichtner S; Hecker H; Schaefer A; Arseniev L; Hertenstein B; Ganser A; Drexler H
    Circulation; 2006 Mar; 113(10):1287-94. PubMed ID: 16520413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study).
    de la Fuente LM; Stertzer SH; Argentieri J; Peñaloza E; Koziner B; Rouy D; Altman PA
    EuroIntervention; 2011 Nov; 7(7):805-12. PubMed ID: 22082576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.
    Nyolczas N; Gyöngyösi M; Beran G; Dettke M; Graf S; Sochor H; Christ G; Edes I; Balogh L; Krause KT; Jaquet K; Kuck KH; Benedek I; Hintea T; Kiss R; Préda I; Kotevski V; Pejkov H; Dudek D; Heba G; Sylven C; Charwat S; Jacob R; Maurer G; Lang I; Glogar D
    Am Heart J; 2007 Feb; 153(2):212.e1-7. PubMed ID: 17239678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial.
    Ripa RS; Jørgensen E; Wang Y; Thune JJ; Nilsson JC; Søndergaard L; Johnsen HE; Køber L; Grande P; Kastrup J
    Circulation; 2006 Apr; 113(16):1983-92. PubMed ID: 16531621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of left ventricular ejection fraction on clinical long-term follow-up outcomes in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
    Wang CH; Xie XJ; Fang Q; Zhang SY; Fang ZJ; Jiang XF; Xie HZ; Liu ZY; Shen ZJ
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):265-8. PubMed ID: 21418873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction.
    Huikuri HV; Kervinen K; Niemelä M; Ylitalo K; Säily M; Koistinen P; Savolainen ER; Ukkonen H; Pietilä M; Airaksinen JK; Knuuti J; Mäkikallio TH;
    Eur Heart J; 2008 Nov; 29(22):2723-32. PubMed ID: 18845667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.
    Woo JS; Kim W; Ha SJ; Kim JB; Kim SJ; Kim WS; Seon HJ; Kim KS
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial.
    Kang HJ; Lee HY; Na SH; Chang SA; Park KW; Kim HK; Kim SY; Chang HJ; Lee W; Kang WJ; Koo BK; Kim YJ; Lee DS; Sohn DW; Han KS; Oh BH; Park YB; Kim HS
    Circulation; 2006 Jul; 114(1 Suppl):I145-51. PubMed ID: 16820564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
    Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
    Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.
    Traverse JH; Henry TD; Moye' LA
    Am Heart J; 2011 Oct; 162(4):671-7. PubMed ID: 21982659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cells mobilization in acute myocardial infarction (stem-AMI trial): preliminary data of a perspective, randomized, single blind trial.
    Malafronte C; Achilli F
    Minerva Cardioangiol; 2007 Dec; 55(6):721-31. PubMed ID: 18091641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.